How do acalabrutinib and ibrutinib safety profiles compare?
Acalabrutinib (Calquence) shows a better cardiovascular safety profile than ibrutinib (Imbruvica), particularly lower rates of atrial fibrillation, hypertension, and bleeding, due to its higher selectivity for BTK and shorter off-target effects on other kinases. In head-to-head trials like ELEVATE-TN, acalabrutinib plus obinutuzumab had 9.4% grade 3+ atrial fibrillation versus 23.5% with ibrutinib-obinutuzumab, with overall cardiac events at 23% vs. 39%.1 Pooled data from real-world studies confirm acalabrutinib's edge in reducing these risks while maintaining similar efficacy in CLL.3
What specific side effects differ between them?
| Side Effect | Acalabrutinib Incidence | Ibrutinib Incidence | Notes |
|-------------|-------------------------|---------------------|-------|
| Atrial Fibrillation (grade 3+) | 4-10% | 15-24% | Dose-dependent; acalabrutinib's potency allows twice-daily lower dosing.1 |
| Hypertension (grade 3+) | 4-9% | 15-21% | Linked to ibrutinib's ITK inhibition.2 |
| Major Bleeding | 3-5% | 5-9% | Both require caution with anticoagulants; acalabrutinib lower in trials.3 |
| Infections (grade 3+) | 20-30% | 25-35% | Similar; both suppress immunity.1 |
| Diarrhea (any grade) | 35-40% | 45-50% | More common early with ibrutinib.4 |
Acalabrutinib avoids some ibrutinib-linked issues like arthralgias or rash from broader kinase inhibition.5
Why does acalabrutinib cause fewer cardiac issues?
Ibrutinib inhibits multiple kinases (e.g., EGFR, ITK), disrupting vascular homeostasis and promoting arrhythmias. Acalabrutinib is more selective, binding covalently to BTK with faster dissociation, minimizing off-target cardiac toxicity. Preclinical models and phase 3 data (ASCEND trial) back this, with 1-year AF risk at 9.4% for acalabrutinib monotherapy vs. higher ibrutinib benchmarks.2
Are there patient groups where ibrutinib might still be preferable?
In high-risk CLL or post-ibrutinib relapse, efficacy data overlap, but ibrutinib's longer-term data (10+ years) edges out acalabrutinib's shorter follow-up. Ibrutinib may suit patients without cardiac history, though guidelines now favor acalabrutinib first-line for CV risk.7 No head-to-head survival data yet.
What do real-world studies and guidelines say?
NCCN and ESMO guidelines prefer acalabrutinib or zanubrutinib over ibrutinib for CLL due to safety.7 VA database analysis (n=1,327) found 23% lower AF odds with acalabrutinib.3 Market shift reflects this: acalabrutinib sales overtook ibrutinib in CLL by 2023.
Sources